SYRE in the 13F filings
Spyre Therapeutics Inc · CUSIP 00773J202
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 18
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 2 listed it in both
- Shares listed
- 18,600,884
- combined, among listed positions
- Reported value
- $937m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 12 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +343,351.
Managers listing SYRE in Q1 2026
18 of 18 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 666,564 shares now+466,392
- Wellington Management Group LLPexisting position · 1,824,811 shares now+275,527
- Fidelity (FMR LLC)existing position · 11,781,024 shares now+142,205
- Marshall Wace LLPnew position · 139,259 shares now+139,259
- Millennium Management LLCexisting position · 146,639 shares now+70,445
Reductions
- Janus Henderson Group Ltdexisting position · 1,656,164 shares now-172,845
- Invesco Ltdexisting position · 132,390 shares now-18,544
- Balyasny Asset Management LLCexisting position · 55,477 shares now-17,988
- T. Rowe Price Associates Incexisting position · 1,598,730 shares now-3,152
- Tudor Investment Corpexisting position · 8,364 shares now-1,763
New positions and exits
New (3)
Exited (2)
- Point72 Asset Management LPwas $22m
- Brevan Howard Capital Management LPwas $203k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2024 | 3 | $23m | 3 | 0 |
| Q2 2024 | 3 | $25m | 3 | 0 |
| Q3 2024 | 3 | $45m | 2 | 1 |
| Q4 2024 | 4 | $57m | 4 | 0 |
| Q1 2025 | 3 | $15m | 1 | 2 |
| Q4 2025 | 2 | $69m | 13 | 8 |
| Q1 2026 | 5 | $729m | 12 | 7 |
| Q2 2026 | 9 | $2.2bn | 23 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
SYRE and LLY →SYRE and JNJ →SYRE and VRTX →Choose a stock to compare with SYRE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own SYRE, latest filings →Back to the 13F Explorer →